The Technical Analyst
Kiromic BioPharma, Inc. [KRBP]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Kiromic BioPharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
13.65% $3.08
America/New_York / 26 apr 2024 @ 13:32
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.97 mill |
| EPS: | -12.59 |
| P/E: | -0.240 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 1.288 mill |
| Avg Daily Volume: | 0.0069 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.240 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -0.240 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.57 - 3.59 ( +/- 16.46%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-18 | Catlin Michael | Buy | 18 000 | Restricted Stock Award |
| 2024-03-18 | Misajon Pamela | Buy | 18 000 | Restricted Stock Award |
| 2024-03-18 | Nagel Michael | Buy | 18 000 | Restricted Stock Award |
| 2023-10-05 | Bersani Pietro | Buy | 65 600 | Restricted Stock Units |
| 2023-10-05 | Misajon Pamela | Buy | 7 500 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 100.00 |
| Last 47 transactions |
| Buy: 2 001 102 | Sell: 1 131 551 |
Forecast:
15:12 - $2.84
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $3.08 (13.65% ) |
| Volume | 0.0015 mill |
| Avg. Vol. | 0.0069 mill |
| % of Avg. Vol | 21.11 % |
| Signal 1: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KRBP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
KRBP
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Last 10 Buy Signals
Latest Press Releases
2024-04-24 08:08:00 - Press Release
Kiromic Biopharma Reports Consistent Favorable Safety, Tolerability, And Efficacy In Deltacel-01 Clinical Trial First Three Patients
Houston--(business wire)---- $krbp #gdt--kiromic biopharma reports consistent favorable safety, tolerability, and efficacy in deltacel-01 clinical trial first three patients.
2024-04-02 08:18:00 - Press Release
Kiromic Biopharma Reports Favorable Safety, Tolerability, And Early Efficacy From Third Patient In Deltacel-01 Clinical Trial
Houston--(business wire)---- $krbp #gdt--kiromic biopharma reports favorable safety, tolerability, and early efficacy from third patient in deltacel-01 clinical trial.
2024-03-19 08:08:00 - Press Release
Early Efficacy Results Show Primary Lung Tumor Stabilization And Complete Disappearance Of Brain Metastases In Second Patient In Kiromic Biopharma's Deltacel-01 Clinical Trial
Houston--(business wire)---- $krbp #cart--kiromic biopharma, inc. (otcqb: krbp) (“kiromic” or the “company”) reports early efficacy results showing primary lung tumor stabilization and the complete disappearance of brain metastases in the second patient in the company's deltacel-01 phase 1 clinical trial. deltacel-01 is evaluating deltacel™ (kb-gdt-01), kiromic's allogeneic, off-the-shelf, gamma delta t-cell (gdt) therapy, in patients with stage 4 metastatic non-small cell lung cancer (nsclc). preliminary resu.
2024-03-01 08:08:00 - Press Release
Kiromic Biopharma Adds Virginia Oncology Associates, Pc As The Second Clinical Trial Site In The Ongoing Phase 1 Deltacel-01 Trial
Houston--(business wire)---- $krbp #gdt--kiromic biopharma, inc. (otcqb: krbp) (“kiromic” or the “company”) announces that virginia oncology associates, pc (norfolk, virginia) has been activated as the second clinical trial site in the phase 1 deltacel-01 trial evaluating deltacel™ (kb-gdt-01), kiromic's allogeneic, off-the-shelf, gamma delta t-cell (gdt) therapy, in patients with non-small cell lung cancer (nsclc). “virginia oncology associates is known for its excellence in oncology-focused research and pat.
2024-02-28 18:30:00 - Press Release
Kiromic Biopharma To Present At The Otc Markets' Virtual Life Science Investor Forum On March 7th
Houston--(business wire)---- $krbp #gdt--kiromic biopharma, inc. (otcqb: krbp) (“kiromic” or the “company”) announces that chief executive officer pietro bersani, chief financial officer brian hungerford and chief scientific officer and interim operations officer leonardo mirandola, ph.d., will participate in the otc markets' life science investor forum in a fireside chat format, hosted by virtualinvestorconferences.com, on march 7th, 2024. date: march 7, 2024 time: 11:00 a.m. eastern time link: https://bit.l.
Latest News
2024-02-28 18:30:00 - Business Wire
Kiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7th
HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Chief Executive Officer Pietro Bersani, Chief Financial Officer Brian Hungerford and Chief Scientific Officer and Interim Operations Officer Leonardo Mirandola, Ph.D., will participate in the OTC Markets' Life Science Investor Forum in a Fireside Chat format, hosted by VirtualInvestorConferences.com, on March 7th, 2024. Date: March 7, 2024 Time: 11:00 a.m. Eastern time Link: https://bit.l.
2023-03-09 14:31:53 - PennyStocks
10 Hot Penny Stocks Under $1 To Watch This Week
Penny stocks under $1 to watch right now. The post 10 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-09-24 11:31:00 - PennyStocks
Long Term Penny Stocks Investing Strategy (Complete Guide)
Use this guide for investing in penny stocks in the long term The post Long Term Penny Stocks Investing Strategy (Complete Guide) appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-07-07 10:29:03 - Benzinga
Why Kiromic BioPharma Shares Are Trading Higher Today?
Kiromic BioPharma Inc (NASDAQ: KRBP) has completed the construction of its expanded current good manufacturing practice manufacturing facility in Houston. The expanded facility located at Kiromic's headquarters is one of the conditions required for the Company to begin.
2022-07-07 09:30:38 - PennyStocks
Top Penny Stocks To Buy Today? 3 To Watch Under $3
2022-06-21 13:37:02 - Benzinga
Kiromic BioPharma's Prioritizes New Gamma Delta T-Cell Product Candidate
Kiromic BioPharma Inc (NASDAQ: KRBP) has announced a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT. Kiromic expects to submit its first new investigational new drug (IND) application to the FDA in 2H of 2022.
2022-06-07 13:00:44 - InvestorPlace
Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday
We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares. The post Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday appeared first on InvestorPlace.
2022-06-07 12:18:40 - InvestorPlace
Why Is Kiromic BioPharma (KRBP) Stock Up 75% Today?
Kiromic BioPharma (KRBP) stock is rocketing higher on Tuesday following announcing a new sponsored research agreement (SRA). The post Why Is Kiromic BioPharma (KRBP) Stock Up 75% Today?
2022-06-07 10:38:04 - Benzinga
Why Kiromic Biopharma Shares Are Skyrocketing Today
Kiromic Biopharma Inc (NASDAQ: KRBP) shares are trading higher by 78.5% at $0.50 after the company entered a Sponsored Research Agreement (SRA) under which in vivo preclinical data will be generated from Kiromic's Gamma Delta T cell allogeneic therapies. "We believe that the SRA will.
2022-05-05 18:58:32 - PennyStocks
10 Top Penny Stocks To Buy For Under $1 May 2022 Edition
Top penny stocks under $1 to watch in May. The post 10 Top Penny Stocks To Buy For Under $1 May 2022 Edition appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.